About Oncorena
Oncorena AB is a Swedish pharma company founded in 2011, in Gothenburg, with the mission to develop a breakthrough treatment for metastatic renal cancer headquartered in Lund. Our objective is to confirm the powerful anti-tumor activity in preclinical studies and evaluate potential clinical benefits of ONC175 in metastatic renal cancer patients.
Disclaimer
The information on this website is of general information nature and is not intended to replace personal medical advice from doctors and other healthcare professionals. Oncorena’s drug is an investigational drug and is not approved for commercial use.
©2023-2024 Oncorena AB. All content all rights reserved.